About us

Amazing biological discoveries made by young scientists change the world.

We develop bioelectronic medicine for preventing and treating the age-related diseases.
The goal of our research is to help people get rid of pain and enrich the quality of their lives.

Who We Are

In 2013, a team of young scientists studying chemistry, biology and computer engineering at the University of Illinois discovered a treatment protocol that rapidly increases the heart rate variability by using mild electromagnetic signals during a bioelectromagnetics experiment. In the additional clinical studies, the team identified the possibility to restore the balance of the autonomic nervous system and treat age-related chronic diseases.

In 2016, AMO Lab was established as a bioelectronics company in the United States and Korea based on its proprietary neurostimulation platform.

Our Mission

Age-related chronic diseases cause significant economic, personal and social burdens for individuals, families and communities.
Our mission is to delay, halt or even reverse aging, which is the ultimate goal of humanity, with natural, safe therapies without any side effect.

Our Mission

Age-related chronic diseases cause significant economic, personal and social burdens for individuals, families and communities.
Our mission is to delay, halt or even reverse aging, which is the ultimate goal of humanity, with natural, safe therapies without any side effect.

Contact-free Bioelectronic Medicine

AMO+, the first commercial product of AMO Lab, is a consumer wellness product that improves the quality of sleep through a unique non-invasive, contact-free approach for vagus nerve stimulation.
This innovative wearable sleep device has been completed as a result of persistent commitment and clinical studies of young scientists with their vision for the future of bioelectronics.

Contact-free Bioelectronic Medicine

AMO+, the first commercial product of AMO Lab, is a consumer wellness product that improves the quality of sleep through a unique non-invasive, contact-free approach for vagus nerve stimulation.
This innovative wearable sleep device has been completed as a result of persistent commitment and clinical studies of young scientists with their vision for the future of bioelectronics.

Our Funding

We attracted two seed funding from NAVER D2SF and NEOPLY in Korea. In 2019, we will announce a financing of over $10 million in a Series A funding round from venture capitals.

Our Funding

We attracted two seed funding from NAVER D2SF and NEOPLY in Korea. In 2019, we will announce a financing of over $10 million in a Series A funding round from venture capitals.

Our Intellectual Property

We have broad portfolio of intellectual property rights of seven pending patents globally. The patent covers signal processing, treatment methods and noninvasive delivery methods and contains a portion of the critical areas of our technology.

Our Intellectual Property

We have broad portfolio of intellectual property rights of seven pending patents globally. The patent covers signal processing, treatment methods and noninvasive delivery methods and contains a portion of the critical areas of our technology.

Our History

2011

Young scientists studying chemistry, biology and computer engineering formed a research team believing that neuromodulation would change the future.

2013

First prototype of the electromagnetic field stimulator of the size of a cigarette pack was completed.

2014

In the winter of 2014, we discovered the clues to vagus nerve modulation by chance. This was the beginning of our studies on the ‘proof of concept’ of neuromodulation.

2015

From 2014 to 2016, the establishment of the concept of cervicothoracic vagus electromagnetic stimulation (cVES) and the development of the treatment protocol for the regulation of the autonomic nervous system using HRV were proceeded.

2016

AMO Lab was incorporated in Delaware, USA and Uiwang-si, South Korea. Second prototype in a wearable form was completed.

2017

Two pilot tests were conducted over 8 weeks with Tenga (Japan) on the improvement of blood circulation regarding the sexual functions. The test results demonstrated the effectiveness of the treatment in increasing the penile size of morning erection of adult males.

2018

The effectiveness of cVES technology was demonstrated through the clinical trial on the ability to restore the balance of the autonomic nervous system.

2019

We plan to launch our wearable sleep device AMO+ in global market.

Our Partnership

Medical Institutions

Medical Advisor

Korea Government Agency

Investors